This channel includes news on cardiovascular care delivery, including how patients are diagnosed and treated, cardiac care guidelines, policies or legislation impacting patient care, device recalls that may impact patient care, and cardiology practice management.
New federal limits on state-directed payments are set to cut Medicaid funding in most states. Hospitals are expected to bear the brunt since they account for the majority—84%, around $78B a year—of state-directed healthcare spends.
Either the stakeholders issuing the warnings overstated the risk of widespread closings—or COVID-era emergency funds succeeded in heading off a calamity of national proportions. Either way, patient access has taken a hit here and there.
Major TAVR policy changes appear to be on the way—should clinicians be excited or concerned? Leading U.S. medical societies are sharing their early reactions.
The Kentucky-based insurance giant had owned a 40% stake in the hospice company, stemming from its 2021 acquisition of Kindred Healthcare. Humana said a “consortium of investors" is making the buy, but few details were revealed.
The group highlighted the proven effectiveness of these drugs, especially semaglutide and tirzepatide, while noting that eligibility, affordability and availability will still play key roles in any treatment decisions.
From the perspective of management science, healthcare is a complex adaptive system marked by intricate feedback loops and overlapping interdependencies. As such, the sector demands caution by those introducing large-language AI into its tangled webs.
Earlier this year, patients treated by an AI chatbot for some common mental health challenges got better. This was significant because the patients were part of the first randomized and controlled trial for this type of AI intervention.
The EARLY TAVR clinical trial made a significant impact, paving the way for the FDA to approve multiple transcatheter heart valves for the treatment of asymptomatic patients. However, one cardiologist who participated in the trial has some serious concerns with how its findings were presented to the public.